| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 520 | $45.04 | $23,420.80 | -0.9% | |
| Sep 12, 2018 | PAHC Phibro Animal Health Corp | Bendheim Daniel M | Exec. VP, Corporate Strategy | Sell | 2,500 | $44.30 | $110,750.00 | -100% | |
| Sep 12, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 520 | $45.04 | $23,420.80 | -0.9% | |
| Sep 11, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 15,777 | $14.75 | $232,668.99 | -0.2% | |
| Sep 11, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 250,000 | $6.10 | $1,523,875.00 | -7.8% | |
| Sep 10, 2018 | ETST Earth Science Tech, Inc. | Majorca Group, Ltd. | 10% Owner | Sell | 480,000 | $0.75 | $360,000.00 | -1.9% | |
| Sep 10, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 696 | $21.25 | $14,790.14 | -100% | |
| Sep 7, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $106.76 | $19,217,054.68 | - | |
| Sep 7, 2018 | JNJ Johnson & Johnson | Kapusta Ronald A | Controller, CAO | Sell | 7,899 | $137.18 | $1,083,606.94 | -23.5% | |
| Sep 7, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $6.24 | $1,147,240.00 | -0.5% | |
| Sep 6, 2018 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 7,000 | $1.27 | $8,890.00 | +6.9% | |
| Sep 6, 2018 | SNY Sanofi | Sanofi | 10% Owner | Sell | 104,552 | $406.68 | $42,519,249.18 | -0.4% | |
| Sep 6, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 20,000 | $47.14 | $942,718.00 | -16.6% | |
| Sep 6, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 20,000 | $47.14 | $942,718.00 | -16.6% | |
| Sep 5, 2018 | IRWD Ironwood Pharmaceuticals Inc | McHugh Julie53 | Director | Sell | 1,500 | $19.10 | $28,650.00 | -1.6% | |
| Sep 5, 2018 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 2,000 | $19.10 | $38,200.00 | -4.6% | |
| Sep 5, 2018 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | CEO | Sell | 90,776 | $60.18 | $5,463,230.26 | -20.0% | |
| Sep 4, 2018 | HROW Harrow, Inc. | Kammer Robert J | - | Sell | 10,000 | $3.00 | $30,000.00 | -1.1% | |
| Sep 4, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $44.58 | $44,580.00 | -100% | |
| Sep 4, 2018 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 600 | $105.57 | $63,342.00 | -14.5% | |
| Aug 31, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 700 | $14.26 | $9,982.00 | - | |
| Aug 30, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $105.42 | $20,030,370.00 | -0.2% | |
| Aug 30, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 5,752 | $14.31 | $82,333.12 | - | |
| Aug 29, 2018 | CPIX Cumberland Pharmaceuticals Inc | Bonner Michael | Chief Financial Officer | Buy | 400 | $6.00 | $2,400.00 | +1.1% | |
| Aug 28, 2018 | PCRX Pacira Biosciences, Inc. | Kronenfeld Mark A. | Director | Buy | 1,000 | $44.61 | $44,611.20 | +13.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.